Discovery and Optimization of 6-(1-Substituted pyrrole-2-yl)- s-triazine Containing Compounds as Antibacterial Agents

ACS Infect Dis. 2022 Apr 8;8(4):757-767. doi: 10.1021/acsinfecdis.1c00450. Epub 2022 Mar 3.

Abstract

Antimicrobial drug resistance is a major health issue plaguing healthcare worldwide and leading to hundreds of thousands of deaths globally each year. Tackling this problem requires discovery and development of new antibacterial agents. In this study, we discovered novel 6-(1-substituted pyrrole-2-yl)-s-triazine containing compounds that potently inhibited the growth of Staphylococcus aureus regardless of its methicillin-resistant status, displaying minimum inhibitory concentration (MIC) values as low as 1 μM. The presence of a single imidazole substituent was critical to the antibacterial activity of these compounds. Some of the compounds also inhibited several nontubercular mycobacteria. We have shown that these molecules are potent bacteriostatic agents and that they are nontoxic to mammalian cells at relevant concentrations. Further development of these compounds as novel antimicrobial agents will be aimed at expanding our armamentarium of antibiotics.

Keywords: MRSA; antibiotic; biofilm; drug discovery; structure−activity relationship.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / pharmacology
  • Mammals
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Pyrroles / pharmacology
  • Triazines / pharmacology

Substances

  • Anti-Bacterial Agents
  • Pyrroles
  • Triazines